var data={"title":"Belatacept: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Belatacept: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/474870?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=belatacept-patient-drug-information\" class=\"drug drug_patient\">see &quot;Belatacept: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49681161\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Nulojix Shortage Special Alert</span>\n      <span class=\"collapsible-date\">Updated December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-top:2em;\">Bristol-Myers Squibb projects that the supply of Nulojix (belatacept) in 2017 will not be sufficient to enable new patients to start treatment, and that, effective March 15, 2017, it will not be able to supply Nulojix for new patients. To ensure existing patients continue to receive Nulojix, they must be registered in the Nulojix Distribution Program and receive a unique patient identification number which will be required when placing orders for the drug. McKesson Plasma and Biologics will be the exclusive distributor of Nulojix and may be contacted at 1-877-625-2566 to confirm an existing account and/or establish a purchasing relationship.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Further information may be found at http://www.nulojixhcp.bmscustomerconnect.com/servlet/servlet.FileDownload?file=00Pi000000nzpG5EAI.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12993081\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Posttransplant lymphoproliferative disorder, other malignancies, and serious infections:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Increased risk for developing posttransplant lymphoproliferative disorder, predominantly involving the CNS. Recipients without immunity to Epstein-Barr virus are at a particularly increased risk; therefore, use in Epstein-Barr virus&ndash;seropositive patients only. Do not use belatacept in transplant recipients who are Epstein-Barr virus seronegative or with unknown Epstein-Barr virus serostatus.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Only health care providers experienced in immunosuppressive therapy and management of kidney transplant patients should prescribe belatacept. Manage patients receiving the drug in facilities equipped and staffed with adequate laboratory and supportive medical resources. The health care provider responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Increased susceptibility to infection and the possible development of malignancies may result from immunosuppression.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Use in liver transplant patients is not recommended because of an increased risk of graft loss and death.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13034487\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Nulojix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12923451\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Selective T-Cell Costimulation Blocker</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12993240\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosing is based on actual body weight at the time of transplantation; do not modify weight-based dosing during course of therapy unless the change in body weight is &gt;10%. The prescribed dose must be evenly divisible by 12.5 mg to allow accurate preparation of the reconstituted solution using the provided required disposable syringe for preparation. For example, the calculated dose for a 64 kg patient: 64 kg x 10 mg per kg = 640 mg. The nearest doses to 640 mg that are evenly divisible by 12.5 mg would be 637.5 mg or 650 mg; the closest dose to the calculated dose is 637.5 mg, therefore, 637.5 should be the actual prescribed dose for the patient.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Kidney transplant, prophylaxis of organ rejection:</b> IV: <b>Note: </b>Use in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial phase: 10 mg/kg on day 1 (day of transplant, prior to implantation) and on day 5 (~96 hours after day 1 dose), followed by 10 mg/kg at the end of week 2, week 4, week 8, and week 12 following transplantation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance phase: 5 mg/kg every 4 weeks (plus or minus 3 days) beginning at the end of week 16 following transplantation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Conversion from calcineurin inhibitor (off-label dosing)</i> (Grinyo 2012; Grinyo 2016; Rostaing 2011): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial phase: 5 mg/kg on transition days 1, 15, 29, 43, and 57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance phase: 5 mg/kg every 4 weeks beginning 4 weeks after completion of the initial phase. <b>Note</b>: Taper calcineurin inhibitor dose slowly over 1 month (no reduction on day 1, 40% to 60% reduction on day 15, 70% to 80% reduction on day 23; discontinue on day 29 and beyond).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Lung transplant, prophylaxis of organ rejection (off-label use):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial phase: 10 mg/kg on days 0 and 4, and again at weeks 2 and 4 (Timofte 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance phase (for chronic treatment patients only): 10 mg/kg every month beginning 4 weeks after completion of the initial phase (Timofte 2016)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24932356\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12993342\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, renal function did not affect clearance in pharmacokinetic studies of kidney transplant patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12993343\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, hepatic function did not affect clearance in pharmacokinetic studies of kidney transplant patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12993318\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nulojix: 250 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12993087\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14729159\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The ENLiST registry has been created to further determine the safety of belatacept, particularly the incidence of post-transplant lymphoproliferative disorder (PTLD), CNS PTLD, and progressive multifocal leukoencephalopathy (PML), in U.S. adult EBV-seropositive kidney transplant patients. Transplant centers are encouraged to participate (1-800-321-1335).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Effective March 15, 2017, Bristol-Myers Squibb will not be able to supply Nulojix for new patients. To ensure existing patients continue to receive Nulojix, they must be registered in the Nulojix Distribution Program and receive a unique patient identification number which will be required when placing orders for the drug. McKesson Plasma and Biologics will be the exclusive distributor of Nulojix and may be contacted at 1-877-625-2566 or more information may be found at: http://www.nulojixhcp.bmscustomerconnect.com/servlet/servlet.FileDownload?file=00Pi000000nzpG5EAI. BMS anticipates that it will be able to supply Nulojix to new patients again in 2018.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12993083\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125288s070lbl.pdf#page=44&amp;token=RE89k5QcYHWfjOlJd/lCuZPJloaeyfIXuGvry2HyT7baOGqlT7sHW+8wFX9pI0cQXCMNGwl3W94dYLSJlGlkmPxsN4UuPoPC0Db1aMysYeHE6ft9OuwFrSluFtlO9DvY&amp;TOPIC_ID=16790\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125288s070lbl.pdf#page=44</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12993241\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer as an IV infusion over 30 minutes using an infusion set with a 0.2 to 1.2 micron low protein-binding filter. The infusion must be completed within 24 hours of reconstitution of the lyophilized powder. Infuse in a separate line from other infused agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12922990\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Kidney transplant (de novo use):</b> Prophylaxis of organ rejection concomitantly with basiliximab induction, mycophenolate, and corticosteroids in adult Epstein-Barr virus (EBV) seropositive kidney transplant recipients</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Use only in EBV seropositive patients; use for prophylaxis of organ rejection in transplanted organs other than the kidney has not been established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49912910\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Lung transplant, prophylaxis of organ rejection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25707958\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12993095\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Incidences reported as part of a combination therapy regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (34%), hypertension (32%), hypotension (18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (21%), insomnia (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypokalemia (21%), hyperkalemia (20%), hypophosphatemia (19%), lipid metabolism disorder (19%), hyperglycemia (16%), hypocalcemia (13%), hypercholesterolemia (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (39%), constipation (33%), nausea (24%), vomiting (22%), abdominal pain (19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (37%), dysuria (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (45%), leukopenia (20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (72% to 82%, serious infection 24% to 36%), fungal infection (18%), herpes virus infection (7% to 14%), cytomegalovirus disease (11% to 13%), influenza (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (17%), back pain (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Proteinuria (16%; up to 33% 2+ proteinuria at 1 month post-transplant), graft complications (renal: 25%), hematuria (16%), increased serum creatinine (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (24%), upper respiratory tract infection (15%), nasopharyngitis (13%), dyspnea (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (28%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Arteriovenous fistula site complication (thrombosis, &lt;10%), atrial fibrillation (&lt;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety (10%), Guillain-Barr&eacute; syndrome (&lt;10%), dizziness (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (&lt;10%), hyperhidrosis (&lt;10%), acne vulgaris (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Diabetes mellitus (new onset, 5% to 8%), hypomagnesemia (7%), hyperuricemia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Stomatitis (&lt;10%; including aphthous stomatitis), upper abdominal pain (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary incontinence (&lt;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hematoma (&lt;10%), lymphocele (&lt;10%), neutropenia (&lt;10%), malignant neoplasm (4%), malignant neoplasm of skin (nonmelanoma, 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Polyoma virus infection (3% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Musculoskeletal pain (&lt;10%), tremor (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Acute renal failure (&lt;10%), hydronephrosis (&lt;10%), kidney transplant dysfunction (chronic allograft nephropathy: &lt;10%), renal disease (renal artery stenosis: &lt;10%), renal insufficiency (&lt;10%), renal tubular necrosis (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis (10%), tuberculosis (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Infusion related reaction (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, aspergillosis (cerebral; higher dosing regimen), encephalitis (Chagas, West Nile; higher dosing regimen), graft rejection (renal), lymphoproliferative disorder (post transplant; incidence is 9-fold higher in non-EBV seropositive patients), meningitis (cryptococcal), nephropathy (polyoma virus-associated mainly BK), progressive multifocal leukoencephalopathy (higher dosing regimen)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12993092\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Transplant patients who are Epstein-Barr virus (EBV) seronegative or with unknown EBV serostatus due to increased risk for post transplant lymphoproliferative disorder (PTLD).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12993093\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: <b>[US Boxed Warning]: Risk for infection is increased.</b> Immunosuppressive therapy may lead to bacterial, viral (cytomegalovirus [CMV] and herpes), fungal, and protozoal infections, including opportunistic infections (may be fatal). Tuberculosis (TB) is increased; test patients for latent TB prior to initiation, and treat latent TB infection prior to use. Prophylaxis for cytomegalovirus (CMV) is recommended for at least 3 months after transplantation; prophylaxis for <i>Pneumocystis jirovecii</i> is recommended after transplantation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latent viral infections: Patients receiving immunosuppressive therapy are at an increased risk of activation of latent viral infections, including John Cunningham virus (JCV) and BK virus infection. Activation of JCV may result in progressive multifocal leukoencephalopathy (PML), a rare and potentially-fatal condition affecting the CNS. Symptoms of PML include apathy, ataxia, cognitive deficiencies, confusion, and hemiparesis. Polyoma virus-associated nephropathy (PVAN), primarily from activation of BK virus, may also occur and lead to the deterioration of renal function and/or renal graft loss. Risk factors for the development of PML and PVAN include immunosuppression and treatment with immunosuppressant therapy. The onset of PML or PVAN may warrant a reduction in immunosuppressive therapy; however, in transplant recipients, the risk of reduced immunosuppression and graft rejection should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lymphoproliferative disorders: <b>[US Boxed Warning]: Risk of post-transplant lymphoproliferative disorder (PTLD) is increased, primarily involving the CNS,</b> in patients receiving belatacept compared to patients receiving cyclosporine-based regimens. Degree of immunosuppression is a risk factor for PTLD developing; do not exceed recommended dosing. Patients who are Epstein-Barr virus (EBV) seronegative are at an even higher risk; use is contraindicated in patients without evidence of immunity to EBV. Cytomegalovirus (CMV) infection and T-cell depleting therapy also increases the risk for PTLD; T-cell depleting therapies to treat acute rejection should be used with caution. CMV prophylaxis is recommended for a minimum of 3 months following transplantation. Although CMV disease is a risk for PTLD and CMV seronegative patients are at an increased risk for CMV disease, the clinical role, if any, of determining CMV serology to determine risk of PTLD development has not been determined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: <b>[US Boxed Warning]: Risk for malignancy is increased.</b> Malignancy, including skin malignancy and PTLD, is associated with the use of belatacept; patients should be advised to limit their exposure to sunlight/UV light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Coadministration with anti-thymocyte globulin: In postmarketing reports, venous thrombosis of the renal allograft has occurred in de novo kidney transplant patients, some with other predisposing venous thrombosis risk factors, when the initial anti-thymocyte globulin dose was coadministered (at the same or nearly the same time) with belatacept; if administering anti-thymocyte globulin or any other cell-depleting induction therapy concomitantly with belatacept, separate the dosing by 12 hours. Use with caution in these patients as concurrent administration may increase renal allograft venous thrombosis risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <b>[US Boxed Warning]: Therapy is not recommended in liver transplant patients due to increased risk of graft loss and death.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Corticosteroid minimization: Increased rate and grade of acute rejection, particularly grade 3 rejection, and graft loss has been observed with belatacept when corticosteroids were minimized to 5 mg daily between day 3 and week 6 post-transplant; corticosteroid dosing should be consistent with clinical trial experience (ie, tapered to ~15 mg [10 to 20 mg] daily by the first 6 weeks post-transplant and remain at ~10 mg [5 to 10 mg] daily for the first 6 months post-transplant).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; EBV serostatus: Therapy is only appropriate in patients who are EBV seropositive via evidence of acquired immunity, such as presence of IgG antibodies to viral capsid antigen [VCA] and EBV nuclear antigen [EBNA].</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of a physician experienced in immunosuppressive therapy.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Immunization with live vaccines should be avoided during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298820\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13119731\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16790&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antithymocyte Globulin (Equine): May enhance the adverse/toxic effect of Belatacept. Specifically, the risk for venous thrombosis of the renal allograft may be increased. Management: A 12-hour interval between administration of these 2 agents is suggested if these agents are to be used concomitantly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antithymocyte Globulin (Rabbit): May enhance the adverse/toxic effect of Belatacept. Specifically, the risk for venous thrombosis of the renal allograft may be increased. Management: A 12-hour interval between administration of these 2 agents is suggested if these agents are to be used concomitantly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Belatacept may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12993088\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12993089\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in animal reproduction studies.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The National Transplantation Pregnancy Registry (NTPR) is a registry which follows pregnancies which occur in maternal transplant recipients or those fathered by male transplant recipients. The NTPR encourages reporting of pregnancies following solid organ transplant by contacting them at 877-955-6877 or NTPR@giftoflifeinstitute.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12993091\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if belatacept is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12993247\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for new-onset or worsening neurological, cognitive, or behavioral signs/symptoms; signs/symptoms of infection or malignancy; gastrointestinal side effects (eg, nausea, vomiting, diarrhea); TB screening prior to therapy initiation; EBV serostatus verification prior to therapy initiation (only use belatacept in seropositive patients); potassium, magnesium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12993125\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Fusion protein which acts as a selective T-cell (lymphocyte) costimulation blocker by binding to CD80 and CD86 receptors on antigen presenting cells (APC), blocking the required CD28 mediated interaction between APCs and T cells needed to activate T lymphocytes. T-cell stimulation results in cytokine production and proliferation, mediators in immunologic rejection associated with kidney transplantation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12993149\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>: 0.11 L/kg (transplant patients)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~10  days (healthy patients and kidney transplant patients)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322906\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Nulojix Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (1): $1,135.46</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13733207\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Nulojix (AR, AT, AU, BB, CH, CZ, DE, DK, EE, ES, FR, GB, HR, HU, IE, IL, IT, LT, MT, NL, NO, PL, PT, RO, SA, SE, SI, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Durrbach A, Pestana JM, Pearson T, et al, &ldquo;A Phase III Study of Belatacept versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT-EXT Study),&rdquo; <i>Am J Transplant</i>, 2010, 10(3):547-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/belatacept-drug-information/abstract-text/20415898/pubmed\" target=\"_blank\" id=\"20415898\">20415898</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25285956\"></a>Enderby CY, Habib P, Patel PC, Yip DS, Orum S, Hosenpud JD. Belatacept maintenance in a heart transplant recipient. <i>Transplantation</i>. 2014;98(7):e74-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/belatacept-drug-information/abstract-text/25285956/pubmed\" target=\"_blank\" id=\"25285956\">25285956</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22816557\"></a>Grinyo J, Alberu J, Contieri FL, et al. Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study. <i>Transpl Int</i>. 2012;25(10):1059-1064.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/belatacept-drug-information/abstract-text/22816557/pubmed\" target=\"_blank\" id=\"22816557\">22816557</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27889299\"></a>Griny&oacute; JM, Del Carmen Rial M, Alberu J, et al. Safety and efficacy outcomes 3 years after switching to belatacept from a calcineurin inhibitor in kidney transplant recipients: results from a phase 2 randomized trial. <i>Am J Kidney Dis</i>. 2016;pii:S0272-6386(16):30572-30578.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/belatacept-drug-information/abstract-text/27889299/pubmed\" target=\"_blank\" id=\"27889299\">27889299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25041339\"></a>Klintmalm GB, Feng S, Lake JR, et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. <i>Am J Transplant</i>. 2014;14(8):1817-1827.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/belatacept-drug-information/abstract-text/25041339/pubmed\" target=\"_blank\" id=\"25041339\">25041339</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Latek R, Fleener C, Lamian V, et al, &ldquo;Assessment of Belatacept-Mediated Costimulation Blockade Through Evaluation of CD80/86-Receptor Saturation,&rdquo; <i>Transplantation</i>, 2009, 87(6):926-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/belatacept-drug-information/abstract-text/19300198/pubmed\" target=\"_blank\" id=\"19300198\">19300198</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levy GA, &ldquo;Progress in Transplantation,&rdquo; <i>Ther Drug Monit</i>, 2010, 32(3):246-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/belatacept-drug-information/abstract-text/20418803/pubmed\" target=\"_blank\" id=\"20418803\">20418803</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin ST, Tichy EM, and Gabardi S, &ldquo;Belatacept: A Novel Biologic for Maintenance Immunosuppression After Renal Transplantation,&rdquo; <i>Pharmacotherapy</i>, 2011, 31(4):394-407.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/belatacept-drug-information/abstract-text/21449628/pubmed\" target=\"_blank\" id=\"21449628\">21449628</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nulojix (belatacept) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rostaing et al. Switch from CNI based regimen to a belatacept based regimen in renal transplant recipients. A Randomized Phase II study. Clin J AM Soc Nephrol 2011;6(2):430</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26678245\"></a>Timofte I, Terrin M, Barr E, et al. Belatacept for renal rescue in lung transplant patients.<i>Transpl Int</i>. 2016;29(4):453-463.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/belatacept-drug-information/abstract-text/26678245/pubmed\" target=\"_blank\" id=\"26678245\">26678245</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20415897\"></a>Vincente F, Charpentier B, Vanrenterghem Y, et al. A phase lll study of belatacept based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). <i>Am J Transplant</i>. 2010;10(3):535-546.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/belatacept-drug-information/abstract-text/20415897/pubmed\" target=\"_blank\" id=\"20415897\">20415897</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16790 Version 100.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F49681161\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F12993081\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F13034487\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F12923451\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F12993240\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F24932356\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F12993342\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F12993343\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F12993318\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F12993087\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F14729159\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F12993083\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F12993241\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F12922990\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F49912910\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F25707958\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F12993095\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F12993092\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F12993093\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298820\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F13119731\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F12993088\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F12993089\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F12993091\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F12993247\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F12993125\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F12993149\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322906\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F13733207\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/16790|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=belatacept-patient-drug-information\" class=\"drug drug_patient\">Belatacept: Patient drug information</a></li></ul></div></div>","javascript":null}